marathon
Duchenne drug poised to cost $35,000 but with major catch
May 9, 2017Manufacturing and Production, Sales and Marketing Duchenne Muscular Dystrophy, PTC Therapeutics, marathon
For those that have not followed the story, Emflaza was successfully taken through the FDA regulatory process by Marathon as …
Marathon’s major misstep shows that drug pricing debate is here to stay
February 14, 2017Manufacturing and Production, Sales and Marketing Duchenne Muscular Dystrophy, Emflaza, marathon
Marathon Pharmaceuticals’ approval, last week, by the FDA for its treatment for Duchenne muscular dystrophy would usually have been cause …
FDA approves first treatment for Duchenne muscular dystrophy
February 10, 2017Medical Communications, Sales and Marketing Duchenne Muscular Dystrophy, FDA, marathon, marathon pharmaceuticals
The FDA has announced that it has approved Emflaza (deflazacort), developed by Marathon Pharmaceuticals. The treatment will arrive on the …
FDA accepts Marathon’s Duchenne drug for priority review
August 11, 2016Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, FDA, deflazacort, marathon, marathon pharmaceuticals
Marathon Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted and granted a priority review for …
Latest content
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
Danish medical cannabis use rises as regulator reports no new safety signals
